1.
|
Phase: Phase IV Type: Prevention Status: Closed Age: 12 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 106636, NCT00534638
|
|
2.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000441189, NCI-04-C-N191, NCI-590299/009, GSK-590299/009, NCT00128661
|
|
3.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 104772, NCT00250276
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 26 and older Sponsor: Pharmaceutical / Industry Protocol IDs: 104820, NCT00294047
|
|
5.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 106001, NCT00306241
|
|
6.
|
Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 10 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107476 (M18), 107477, 107479, 107481, NCT00337818
|
|
7.
|
Phase: Phase III Type: Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 104479, NCT00344032
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 105926, NCT00345878
|
|
9.
|
Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 10 to 14 Sponsor: Pharmaceutical / Industry Protocol IDs: 104896 (month 18 FU), 104902, 104904, 104918, NCT00316706
|
|
10.
|
Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 11 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 107682, NCT00369824
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 108933, NCT00423046
|
|
12.
|
Phase: Phase III Type: Prevention Status: Completed Age: 10 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 108464, NCT00426361
|
|
13.
|
Phase: Phase III Type: Prevention Status: Completed Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 109801, NCT00456807
|
|
14.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 10 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 106069, NCT00481767
|
|
15.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107291, NCT00485732
|
|
16.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 10 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 110168, NCT00492544
|
|
17.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 109179, NCT00552279
|
|
18.
|
Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 110886, NCT00578227
|
|
19.
|
Phase: Phase III Type: Prevention Status: Completed Age: 20 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 111567, NCT00637195
|
|
20.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 111507, NCT00652938
|
|
21.
|
Phase: Phase III Type: Prevention Status: Completed Age: 15 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: 103514, 105879, 105880, 105881, 105882, NCT00196937
|
|
22.
|
Phase: Phase III Type: Prevention Status: Closed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107638, NCT00779766
|
|
23.
|
Phase: Phase III Type: Prevention Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111955, NCT00799825
|
|
24.
|
Phase: Phase III Type: Prevention Status: Completed Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111712, NCT00811798
|
|
25.
|
Phase: Phase III Type: Prevention Status: Closed Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111758, NCT00849381
|